The role of metoclopramide in peroral jejunal biopsy

Abstract

Metoclopramide is known to enhance gastric emptying and stimulate duodenal and small-intestinal peristaltic activity. The effect of the drug on peroral jejunal biopsy was examined in a controlled, double-blind, randomized trial. Forty-nine patients (24 females and 25 males) who required jejunal biopsy for diagnostic purposes were admitted to the study. All the biopsies were performed by the same operator using the Quinton multipurpose suction biopsy tube and applying the same technique. Twenty-four patients ranging in age from 18 to 67 years (mean 44.5) received placebo intravenously (sodium metabisulfite), and 25 patients from 16 to 73 years old (mean 39.9) received 10 mg of metoclopramide intravenously prior to the jejunal intubation. Objective parameters of the study were (1) time in minutes required for the intubation at the biopsy site, ie, the area at the ligament of Treitz, and (2) fluoroscopy time. Intubation time in the placebo group was 22.3±1.9 min (mean±sem) vs 11.3±1.4 min in the metoclopramide group (P<0.001). Fluoroscopy exposure time was 2.47±0.25 in the placebo group vs 1.40±0.12 min in the metoclopramide group (P<0.001). Subjective clinical evaluation of the operator's assessment of the procedure was based on a 0–4 scale (much easier=0, easier=1, average=2, harder=3, and much harder=4). Metoclopramide administration resulted in a significantly easier performance of the procedure (P<0.001) but did not influence patient tolerance. Three patients who received metoclopramide and one receiving placebo developed mild to moderate drowsiness of short duration.

The results of this controlled trial indicate that metoclopramide significantly shortens the time required for jejunal biopsy and reduces fluoroscopy exposure. Its regulatory action on gastrointestinal motility contributes to the easier performance of a valuable diagnostic procedure.